STVN

STVN

Stevanato Group SpA

Revenue grew 100% of years5Y
Hold

Stevanato Group S.p.A. designs and produces drug containment solutions like pre-fillable syringes and vials, along with drug delivery systems and diagnostic solutions for biopharma and healthcare sectors globally. It serves pharmaceutical and life sciences companies.

⚕️ Healthcare NYSE Listed 2021 € EUR
$1,000 invested 5 years ago $1,026today

Score Overview

1 Year
Score
Net Growth-0.06%
Net TrendShrank
Net Income Consistency
Rev Growth7.24%
Rev TrendGrew
Revenue Consistency
5 Years
Score6.3
Net Growth-0.09%
Net Trend60%
Net Income Consistency
Rev Growth44.80%
Rev TrendEvery year
Revenue Consistency
All Time
Score
Net Growth-0.09%
Net Trend60%
Net Income Consistency
Rev Growth44.80%
Rev TrendEvery year
Revenue Consistency

See the full market ranking →

Stevanato Group SpA fundamental performance

Between 2021 and 2025, revenue grew from € 843M to € 1.13B and net income declined from € 134M to € 134M. Revenue increased in 100% of the years measured; net income in 60%.

Stevanato Group SpA currently holds a 5-year HDB Score of 6.3 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 21.25
1 Year2025-08-12
$ 21.75-2.31%
5 Years2021-08-12
$ 20.722.57%
All Time2021-07-16
$ 19.389.66%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026€ 1.22B€ 134M
2025€ 1.13B€ 134M€ 132M
2024€ 1.10B€ 117M€ 98M
2023€ 1.08B€ 145M€ 70M
2022€ 983M€ 142M€ 256M
IPO2021€ 843M€ 134M€ 438M

Explore beyond STVN

You're looking at Stevanato Group SpA. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies